Oncothyreon to present at BIO CEO & Investor Conference

SEATTLE, WA, Feb. 2 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, will present at the 12th Annual BIO CEO & Investor Conference taking place Feb. 8-9, 2010 in New York.

Dr. Kirkman will present at 10 a.m. Eastern Time on Tuesday, Feb. 9. A live and archived webcast of the presentation will be accessible by visiting the Oncothyreon website www.oncothyreon.com under the "News & Events" section.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. The Company's oncology pipeline includes Stimuvax, a therapeutic cancer vaccine being developed by Merck KGaA, currently in Phase 3 trials for non small cell lung cancer and breast cancer and PX-866, a PI3 Kinase inhibitor expected to enter Phase 2 in mid-2010. For more information, visit www.oncothyreon.com.

SOURCE Oncothyreon Inc.